Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Acura Pharmaceuticals ( (ACUR) ) is now available.
On July 3 and July 18, 2025, Acura Pharmaceuticals received loans totaling $200,000 from Abuse Deterrent Pharma, LLC, contributing to a principal balance of $8,394,279 with accrued interest of approximately $740,000. The company faces potential operational scaling back or bankruptcy if additional financing is not secured by early August 2025, which could lead to a complete loss of shareholder value.
More about Acura Pharmaceuticals
Average Trading Volume: 6,800
Technical Sentiment Signal: Sell
Current Market Cap: $13.2K
For an in-depth examination of ACUR stock, go to TipRanks’ Overview page.